Phase I Testing of a Malaria Vaccine Composed of Hepatitis B Virus Core Particles Expressing Plasmodium falciparum Circumsporozoite Epitopes

We report the first phase I trial to assess the safety and immunogenicity of a malaria vaccine candidate, ICC-1132 (Malarivax), composed of a modified hepatitis B virus core protein (HBc) containing minimal epitopes of the Plasmodium falciparum circumsporozoite (CS) protein. When expressed in Escher...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Infect Immun
Main Authors: Nardin, Elizabeth H., Oliveira, Giane A., Calvo-Calle, J. Mauricio, Wetzel, Kristiane, Maier, Carolin, Birkett, Ashley J., Sarpotdar, Pramod, Corado, Michael L., Thornton, George B., Schmidt, Annette
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology (ASM) 2004
Assuntos:
Microbial Immunity and Vaccines
Acceso en liña:https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC523031/
https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15501783/
https://ncbi.nlm.nih.govhttps://doi.org/10.1128/IAI.72.11.6519-6527.2004
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares